Moberg Pharma
Pharmaceutical company developing and commercializing treatments for nail fungus.
MOB | ST
Overview
Corporate Details
- ISIN(s):
- SE0011311596 (+3 more)
- LEI:
- 549300XFXK7DVGDRP410
- Country:
- Sweden
- Address:
- Gustavslundsvagen 42, 167 51 Stockholm
- Website:
- https://www.mobergpharma.com/
- Sector:
- Manufacturing
Description
Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-04-08 16:01 |
Proposed management changes at Moberg Pharma
|
English | PDF • 182.3 KB | ||
| 2019-04-08 16:01 |
Föreslagna ledningsförändringar i Moberg Pharma
|
Swedish | PDF • 176.8 KB | ||
| 2019-04-01 08:30 |
Moberg Pharma påkallar förtida inlösen av obligationer med ISIN SE0007953989
|
Swedish | PDF • 163.1 KB | ||
| 2019-04-01 08:30 |
Moberg Pharma gives notice of early redemption of bonds with ISIN SE0007953989
|
English | PDF • 159.5 KB | ||
| 2019-03-29 22:00 |
Moberg Pharma slutför avyttringen av OTC-verksamheten för 155 miljoner USD
|
Swedish | PDF • 197.5 KB | ||
| 2019-03-29 22:00 |
Moberg Pharma completes the divestment of the OTC-business for USD 155 million
|
English | PDF • 178.8 KB | ||
| 2019-03-22 08:30 |
Moberg Pharma completes enrollment for MOB-015 Phase 3 study in Europe
|
English | PDF • 174.5 KB | ||
| 2019-03-22 08:30 |
Moberg Pharma slutför rekryteringen till fas 3-studien för MOB-015 i Europa
|
Swedish | PDF • 172.9 KB | ||
| 2019-03-15 17:00 |
Kommuniké från Moberg Pharmas extra bolagsstämma den 15 mars 2019
|
Swedish | PDF • 169.8 KB | ||
| 2019-03-15 17:00 |
Bulletin from Moberg Pharma’s Extraordinary General Meeting 15 March 2019
|
English | PDF • 165.2 KB | ||
| 2019-03-04 08:30 |
Moberg Pharma publicerar informationshandling med anledning av den föreslagna a…
|
Swedish | PDF • 2.1 MB | ||
| 2019-03-04 08:30 |
Moberg Pharma publishes information document on the proposed divestment of the …
|
English | PDF • 152.9 KB | ||
| 2019-02-21 08:58 | English | PDF • 34.7 KB | |||
| 2019-02-13 09:45 |
Kallelse till extra bolagsstämma i Moberg Pharma AB (publ)
|
Swedish | PDF • 249.6 KB | ||
| 2019-02-13 09:45 |
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)
|
English | PDF • 246.6 KB |
Automate Your Workflow. Get a real-time feed of all Moberg Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Moberg Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Moberg Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-11 | Mark Beveridge | Other | Buy | 3,000 | 17,730.00 SEK |
| 2021-11-10 | Mark Beveridge | Other | Buy | 3,000 | 17,310.00 SEK |
| 2021-11-09 | Mark Beveridge | Other | Buy | 5,000 | 29,800.00 SEK |
| 2021-02-10 | Cindy Wong | Other | Buy | 5,000 | 31,675.00 SEK |
| 2021-02-09 | Cindy Wong | Other | Buy | 5,000 | 30,800.00 SEK |
Peer Companies
